| Autor: |
CHEN Renliang, CHEN Fengying |
| Jazyk: |
čínština |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Zhongguo linchuang yanjiu, Vol 37, Iss 6, Pp 826-829 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1674-8182 |
| DOI: |
10.13429/j.cnki.cjcr.2024.06.002 |
| Popis: |
Coronary heart disease (CHD) is currently an important cause of mortality among residents in China and worldwide. The incidence of CHD in China is increasing annually. Among the various factors leading to the occurrence of CHD, abnormalities in blood lipids, especially elevated low-density lipoprotein cholesterol(LDL-C), are particularly significant. Epidemiological, genetic, and clinical studies have confirmed its crucial role in the development of CHD. Therefore, effectively controlling LDL-C levels has become paramount in preventing the onset of CHD and reducing mortality rates. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, as novel lipid-lowering medications, effectively lower LDL-C and play a significant role in preventing major adverse cardiovascular events(MACEs). This article provides a review of PCSK9 inhibitors in clinical treatment related to coronary artery atherosclerosis. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
